EMCDDA Home
  • EN
Search

Table TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2011 or most recent year available

Part (iv) New hallucinogen outpatient clients by country and age at first use

Country<1515-1920-2425-2930-3435-3940-4445+Age knownAge not knownTotal
Belgium00000000022
Bulgaria00000000000
Czech Republic00000000000
Denmark03000000303
Germany41630010024630
Estonia:::::::::::
Ireland10100000202
Greece00100000112
Spain112787000043750
France5821110018220
Italy2001600000161632
Cyprus00000000000
Latvia301010000224
Lithuania:::::::::::
Luxembourg:::::::::::
Hungary02100000303
Malta:::::::::::
Netherlands01200000369
Austria04000000404
Poland4:1:::::::::
Portugal500000000000
Romania00000000000
Slovenia:::::::::::
Slovakia00000000000
Finland00000000000
Sweden01010000202
United Kingdom6401795311542229631327
Croatia1::::::::::
Turkey:::::::::::
Norway:::::::::::
Total522438721662241773490
 

Notes:

: Indicates no data are available

(1) Data are from 2010.

(2) In 2011 around 27% of all clients and 32% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.

(3) In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. Caution should be made when comparing data with previous years.

(4) Data are from 2010. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.

(5) In 2010 came into implementation a new national information system implying methodological changes particularly in the registration criteria. Caution should be made when comparing 2010 data with previous years.

(6) Data are from 1st of April 2010 to 31st March 2011.

For more information relative to the treatment centre type, please see Table TDI-7.

See also Table TDI-11 part(i), part(ii)

‘General notes for interpreting data'’ on the Explanatory notes and help page.

Source:

Reitox national reports 2012- Table TDI Outpatient Treatment Centres

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013